DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia

Completed · Phase 1/Phase 2

Conditions studied: Leukemia

In brief

RATIONALE: DTGM fusion protein may be able to locate cancer cells and stop them from growing. PURPOSE: Phase I/II trial to study the effectiveness of DTGM fusion protein in treating patients who have recurrent or refractory acute myeloid leukemia.

Key facts

Study ID

NCT00003840

Run by

Wake Forest University Health Sciences

Starts

2000-10-01

Expected to finish

2005-07-01

Last updated by the study team

2017-01-19

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Comprehensive Cancer Center of Wake Forest University Baptist Medical Center — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.